Dandekar Atul's Form 4 filing
Maze Therapeutics, Inc. (MAZE) · filed Jun 2, 2026
- Accession no.
- 0002050167-26-000013
- Filed
- Jun 2, 2026
- Trade date
- May 29, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $197.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dandekar AtulCIK 0002050167 | Officer (CSBO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Common Stock | MOption exerciseAcquired | +7,500 | $10.42 | +$78,150 | 32,308 | Direct | |
| May 29, 2026 | Common Stock | SSaleDisposed | −7,500 | $26.34 | −$197,550 | 24,808 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Common Stock | MOption exerciseDisposed | −7,500 | $0.00 | $0 | 36,643 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.